Vidac Pharma

HK2-VDAC protein interaction disruptors for oncologic and oncodermatologic diseases.

placeJerusalem, Jerusalem District, Israel calendar_todayFounded 2011 groups9 employees language vidacpharma.com

Innovation

6 patent families (5 granted) — focus: Human necessities, Chemistry & metallurgy; filing pace steady. Cited 972 times.

YearFilings
20171
20184
20194
20204
20215
20222
20244
20252
20261

Social engagement

Social engagement: 697 social following, 10 posts in the last 12 months — below the industry typical range.

Investor mix

2 investors on record.

Investor typeCountShare
Private equity150%
Other / undisclosed150%

Recent activity

24 Jun 2026
Milestone
regulatory
17 Jun 2026
Milestone
regulatory
27 May 2026
Milestone
regulatory
Coming soon